A Single-arm, Open, Phase II Clinical Study of Tislelizumab Combined With Lenvatinib and Gemox Regimen for Transformational Treatment of Potentially Resectable Locally Advanced Malignant Tumors of Biliary System.
Latest Information Update: 31 Oct 2022
At a glance
- Drugs Gemcitabine (Primary) ; Lenvatinib (Primary) ; Oxaliplatin (Primary) ; Tislelizumab (Primary)
- Indications Biliary cancer; Carcinoma; Cholangiocarcinoma; Gallbladder cancer
- Focus Therapeutic Use
- 13 Sep 2022 Results(As of 27 April 2022) assessing efficacy and safety of tislelizumab combined with lenvatinib and GMOX in potentially resectable advanced BTC.presented at the 47th European Society for Medical Oncology Congress
- 04 Sep 2022 Planned End Date changed from 30 Jan 2023 to 30 Dec 2023.
- 04 Sep 2022 Status changed from not yet recruiting to active, no longer recruiting.